国内首款CAR-T产品落地五年背后,创新药械商保支付规模已攀升至152亿元

每日经济新闻
May 22

每经记者|涂颖浩    每经编辑|廖丹     2021年6月,国内首款CAR-T(嵌合抗原受体 T 细胞)细胞治疗产品奕凯达获批上市,开启了中国CAR-T商业化元年。五年后的今天,这款价格在百万元级别的抗癌药交出了一份特殊的“成绩单”。近日发布的《中国创新药械多元支付白皮书(2026)》(以下简称白皮书)显示,截至2025年第三季度,奕凯达累计惠及患者已突破1000位,其中通过...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10